Pharming Group N.V.

Pharming Group N.V. is a biopharmaceutical company that develops and commercializes therapies for rare and ultra-rare diseases with significant unmet medical needs. The company focuses primarily on genetic and immunological conditions. Its commercial portfolio includes RUCONEST, an intravenous recombinant C1 esterase inhibitor replacement therapy for acute hereditary angioedema attacks in adult and adolescent patients, and Joenja (leniolisib), an oral targeted inhibitor for activated phosphoinositide 3-kinase delta syndrome. Pharming provides its therapies to rare disease patients, specialist healthcare providers, and clinical communities.

Pharming maintains registered headquarters in Leiden, the Netherlands, with an additional corporate office in Warren, New Jersey. The company operates multiple upstream manufacturing facilities and specialized animal facilities in the Netherlands and France. Ruconest is commercialized directly in the United States, while Joenja is marketed through internal sales and marketing infrastructure in the United States and the United Kingdom, alongside approvals in Japan, Australia, and Israel.

Summary of the business section of Pharming's latest annual report, written by StockData.

“HAE is a rare genetic condition that occurs in between approximately 1 in 10,000 and 1 in 50,000 people worldwide.”